Topline data presented at AAN annual meeting showed AOC 1001 achieved directional improvements in multiple functional endpoint assessments – myotonia (vHOT), measures of strength (total QMT) and mobility (10mWRT, Timed Up and Go)
AOC 1001 data demonstrate favorable safety/tolerability profile with most adverse events mild or moderate
Topline AOC 1001 data identify dose range for pivotal study; Avidity continues to work to resolve partial clinical hold
Volume 7 of investor and analyst event today at 5:30 p.m. ET in Boston and via webcast
SAN DIEGO, April 27, 2023 /PRNewswire/ — Avidity…
